EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy

In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases. Dr. Wakelee discusses how she approaches initial treatment selection in this setting, emphasizing the importance of central nervous system activity when choosing a first-line strategy. She highlights that therapies with strong intracranial efficacy are particularly relevant given the presence of brain metastases. In addition to efficacy, Dr. Wakelee considers patient-specific factors such as excellent performance status, lack of comorbidities, and the patient’s preference to maintain quality of life. The discussion also reflects on how the evolving evidence base, including both monotherapy and combination approaches, informs decision-making in this scenario. Overall, this segment illustrates how clinicians integrate disease characteristics and patient priorities to individualize first-line treatment selection in EGFR-mutated NSCLC.